Most GLP-1 side effects are gastrointestinal, including nausea, vomiting, diarrhoea and constipation. They are most likely to appear in the first weeks of treatment or after a dose increase, and often ease over time. In the placebo-controlled datasets behind approved product labelling, nausea was reported by 12 to 44 percent of treated adults, while gastrointestinal effects led roughly 3 to 6.6 percent to stop treatment.

Serious events are uncommon, but some symptoms need medical assessment and are part of why these medicines are prescribed and monitored rather than dispensed on request.

Key takeaways

• Most GLP-1 side effects are gastrointestinal, particularly nausea, diarrhoea, vomiting and constipation, and they are most common early in treatment or around dose increases.
• Common side effects do not usually mean treatment has to stop. Across the cited datasets, gastrointestinal effects led to discontinuation in roughly 3 to 6.6 percent of treated adults.
• Serious adverse events are uncommon, but persistent severe abdominal pain, inability to keep fluids down, abdominal swelling with no stool or gas, sudden vision changes, or severe low glucose need prompt medical assessment.
• Some risks, including pancreatitis, thyroid cancer, retinopathy worsening and motility disorders, remain more uncertain than simple cause-and-effect claims suggest.
• Indian guidance supports gradual dose escalation and ongoing monitoring, while product information also covers dehydration, pancreatitis, retinopathy and interactions with insulin or sulfonylureas.
• Clinical supervision matters because a prescriber is assessing both baseline risk and whether treatment should be increased, held, paused or investigated further.

Gastrointestinal symptoms are the ones people ask about first, and they are also the ones the trial data describe best. The figures below come from three separate placebo-controlled label datasets covering 718, 2,116 and 3,384 exposed adults, in trials running between 32 and 68 weeks, across both diabetes and weight-management populations.

Each range therefore spans different medicines, different indications and different trial designs. Read them as a description of what the class does, not as a league table. The bottom and top of any range come from different study populations, and treating the gap between them as a ranking of one product against another would misuse the data they were drawn from. One of the medicines usually grouped under this heading is a dual GIP and GLP-1 receptor agonist rather than a pure GLP-1 receptor agonist, which is a further reason the arms are not interchangeable.

Reported effects across these datasets included:

• Nausea: 12 to 44% of treated adults, compared with 4 to 16% on placebo
• Diarrhoea: 12 to 30%, compared with 9 to 16%
• Vomiting: 5 to 24%, compared with 2 to 6%
• Constipation: 6 to 24%, compared with 1 to 11%
• Abdominal pain: 5 to 20%, compared with 3 to 10%
• Fatigue: 7.5 to 11%, compared with 4.6 to 5%
• Reduced appetite: 5 to 11%, compared with 1%
• Reflux: 1.7 to 5%, compared with 0.4 to 3%

The placebo figures repay a second look. Constipation was reported by up to 11 percent of participants receiving no active medicine at all, diarrhoea by up to 16 percent and abdominal pain by up to 10 percent. Symptoms that appear during treatment are not automatically caused by it, which is part of why an assessment by the prescriber is more useful than matching a symptom against a list. The reduced-appetite range is narrower than the others: it comes from one pooled diabetes dataset rather than from all three.

Common is also not the same as treatment-ending. Across the same datasets, gastrointestinal effects led to discontinuation in roughly 3 to 6.6 percent of treated adults, against 0.4 to 0.8 percent on placebo. Where the labels break that down by event:

• Nausea: 1.8 to 2.9%
• Vomiting: 1.2 to 1.7%
• Diarrhoea: 0.7 to 1.4%

For constipation, abdominal pain, reduced appetite, fatigue and reflux, event-specific discontinuation is not reported in these tables at all, so no figure is quoted for them here rather than one being estimated.

Timing is the most practically useful thing in the dataset, and it is consistent across the labels.

• Early treatment: Nausea, vomiting and diarrhoea concentrate at the start of treatment.
• Dose increases: These symptoms also cluster around each dose increase.
• Over time: They generally decrease as treatment continues.

In one pooled dataset, fatigue-type events were reported mainly in the first 12 weeks and often appeared alongside gastrointestinal symptoms rather than separately. A symptom that appears a few days after an increase and is already improving a week later follows the pattern described in the trials. One that begins months into stable treatment, or gets worse rather than better, does not.

That pattern is why dose increases are staged rather than immediate. These medicines slow gastric emptying and act on appetite and gut motility, so going straight to full exposure would predictably worsen nausea, vomiting and diarrhoea. Product labelling states that gradual escalation is intended to reduce gastrointestinal adverse reactions, and the concentration of events around each increase supports that rationale.

No schedule, interval or dose figure is reproduced here, because a schedule read outside a consultation can encourage self-management of a prescription.

More importantly, escalation acts as a tolerability checkpoint, not only a route to a target dose. Between one step and the next, a prescriber can:

• Defer the increase;
• Hold treatment where the applicable labelling permits;
• Check hydration and kidney function; and
• Distinguish a transient effect from something that needs investigating.

Removing that checkpoint also removes a scheduled opportunity for a trained prescriber to assess how the treatment is actually going.

Serious adverse events are rare in the trial record, but they are the reason the class carries warnings at all. Incidence below is quoted as ranges across label datasets for the same reason as before: the underlying trials differ in population, indication and length, and the figures are not a comparison between products.

• Acute pancreatitis: Adjudicated cases were reported at 0.2 to 0.3 per 100 patient-years on treatment, against under 0.1 to 0.2 per 100 patient-years in comparison arms. In one two-year trial, the rate was lower on treatment than on placebo, at 0.27 against 0.33. Prior pancreatitis is treated in labelling as a caution and an uncertain-risk group rather than a quantified predictor.
• Gallbladder disease: Gallstones occurred in 1.6 to 2.5% of treated participants, against 0.7 to 1%, while gallbladder inflammation occurred in 0.6 to 0.8%, against 0.2 to 0.4%. Risk appears higher with weight-management use, longer exposure and higher doses. Rapid or substantial weight loss also independently raises gallstone risk.
• Acute kidney injury: One obesity trial set reported 0.4 cases per 100 patient-years, against 0.2 in comparison groups. Other labels rely on postmarketing reports, including some cases requiring dialysis. These events are usually secondary to dehydration from sustained vomiting or diarrhoea, with risk emphasised at treatment initiation, around dose increases, and in people with existing kidney vulnerability.
• Hypoglycaemia: Risk is low when these medicines are used alone. In one trial, readings below the low-glucose threshold occurred in 28.2% of participants when treatment was added to a sulfonylurea, against 12.7%. When added to basal insulin, the figures were 14 to 19%, against 13%. Insulin and insulin secretagogues are the recognised risk factors.
• Worsening diabetic retinopathy: In SUSTAIN-6, a two-year cardiovascular trial involving 3,297 participants, complications occurred in 3.0% of treated participants, against 1.8%. Among those with retinopathy at baseline, the figures were 8.2% against 5.2%. Higher-risk groups included people with pre-existing retinopathy, poor prior glucose control, insulin use, and rapid early improvement in glucose.
• Severe gastrointestinal reactions, gastroparesis and ileus: Severe gastrointestinal reactions were reported in up to 4.8% of treated participants, against up to 1.4% on placebo. Ileus appears only in postmarketing reporting, where labelling states that it is not always possible to reliably estimate frequency or establish causation. Delayed gastric emptying is pharmacologically expected, while labelling does not recommend use in severe gastroparesis.

A short list of symptoms belongs in a different category from all of this because they change the plan rather than the dose. These include:

• Persistent severe abdominal pain;
• An inability to keep fluids down;
• Abdominal swelling with no stool or gas passing;
• A sudden change of vision in one eye; and
• Low glucose severe enough that a person cannot treat it themselves.

Some symptoms need urgent assessment, while others may be appropriate for a same-day appointment. The difference depends on the symptom and its severity, which is why it helps to know which GLP-1 symptoms need a doctor and how quickly to seek care.

Several of the risk groups above are also the reason a clinician may decide these medicines are not appropriate to start for a particular person.

The evidence is less clear for four possible risks discussed below. Three have already appeared in the trial data above, while thyroid cancer is considered mainly through observational evidence. In each case, the link remains uncertain.

Thyroid cancer is the fear that circulates most widely, and the human evidence on it points in both directions.

The concern is specific to medullary thyroid cancer, a rare cancer arising from the thyroid's C-cells. It does not refer to papillary thyroid cancer, which is the common type, or to an underactive thyroid, which is unrelated.

Dr. Nitin, an endocrinologist at Christian Medical College, Vellore, made the same distinction in a Voy conversation on GLP-1 myths: "Hypothyroidism has got nothing to do with thyroid cancer. The common thyroid cancer that we see in clinical practice is the papillary thyroid cancer, which again has nothing to do with this particular drug."

The concern originates in rodent studies, where these medicines caused C-cell tumours at clinically relevant exposures. Product labelling states that the relevance of those findings to humans has not been determined.

Human studies point in different directions:

• A French case-control study published in 2023 associated one to three years of use with a higher risk of thyroid cancer overall, with an adjusted hazard ratio of 1.58, and medullary thyroid cancer, with a hazard ratio of 1.78 and a 95 percent confidence interval of 1.04 to 3.05. The design is vulnerable to closer thyroid testing among treated patients.
• A Scandinavian cohort of 145,410 users across Denmark, Norway and Sweden found no increase, with a hazard ratio of 0.93 (0.66 to 1.31). Its estimate for medullary thyroid cancer was too imprecise to interpret either way.
• Postmarketing cases of medullary thyroid cancer have also been reported in people treated with liraglutide, but labelling states that those reports can neither establish nor exclude a causal link.

The practical consequence is narrower and firmer than the evidence on causation. Both product labelling and the Endocrine Society of India's 2025 obesity guideline list a personal or family history of medullary thyroid cancer or multiple endocrine neoplasia type 2 as a contraindication. That is why thyroid and family history is reviewed before treatment starts.

Pancreatitis is the clearest case of a real warning with an uncertain magnitude of risk.

Labels carry a warning and adjudicated cases exist in the trial programmes. However, a 2025 systematic review of 62 randomised trials covering 66,232 participants over a mean of 43.5 weeks found a relative risk of 1.44 that was no longer statistically significant once results were stratified by background medication.

The review also excluded a large number of trials in which no pancreatitis events occurred, which limits what the pooled estimate can establish.

The practical interpretation is:

• The warning is real;
• The hallmark symptoms are worth knowing; but
• The size of any additional risk remains uncertain.

Part of the association may also run through the gallbladder. Gallstones are among the commonest causes of acute pancreatitis generally. Eating less and losing weight quickly can also reduce how often the gallbladder empties, favouring sludge and stone formation. The same pattern is seen after bariatric surgery and very-low-calorie diets without these medicines.

Retinopathy worsening is not supported as a uniform class effect.

The strongest signal came from one semaglutide cardiovascular trial. By contrast, a meta-analysis of six placebo-controlled cardiovascular trials across the class found no overall association, with an odds ratio of 1.10 and a 95 percent confidence interval of 0.93 to 1.30.

What did correlate with retinopathy events was the size of the fall in HbA1c. A post-hoc analysis also points towards rapid early improvement in glucose among people who already had eye disease.

That suggests a different clinical explanation from direct drug toxicity: rapid improvement in glucose may temporarily worsen existing retinopathy in susceptible people. It is one reason eye history is reviewed before treatment.

Motility disorders are the hardest of the four to put a number on.

Reliable trial incidence is not available for ileus and gastroparesis because voluntary postmarketing reports do not provide a denominator.

A later US new-user cohort involving 313,342 matched pairs found composite motility events at 1.02 per 100 person-years, against 0.75 among people starting an SGLT2 inhibitor over a median of 5.2 months, a hazard ratio of 1.37 with a 95 percent confidence interval of 1.30 to 1.45. The absolute risk remained around 1 percent or less.

Because this was an observational study, residual confounding remains possible. The data therefore suggest an association but do not establish a clean causal estimate.

One important limitation applies across all four risks: no primary Indian dataset providing nationally representative incidence for these adverse effects was identified.

The figures above therefore come predominantly from non-Indian regulatory trial programmes and observational datasets. They are useful for understanding the evidence base, but they should not be read as India-specific incidence estimates.

Indian professional guidance on this class is thinner than many readers may expect.

The Endocrine Society of India's 2022 obesity guideline recommends:

• Monitoring weight loss and adverse events at least monthly for the first three months;
• Monitoring at least every three months after that; and
• Discontinuing or changing pharmacotherapy where safety or tolerability becomes a problem.

Its 2025 update addresses liraglutide, semaglutide and tirzepatide by name. It lists pancreatitis, acute gallbladder disease and acute kidney injury among their warnings, and suggests ways to reduce gastrointestinal effects, including starting low, increasing slowly, and eating smaller, more frequent meals. It also advises evaluating for conditions such as gastroparesis and gallbladder disease to reduce the risk of drug-related adverse events, and lists hypoglycaemia among liraglutide's adverse effects.

However, the update does not:

• Restate a monitoring schedule;
• Set out a stop-and-continue protocol; or
• Address diabetic retinopathy, or give any instruction on adjusting insulin or sulfonylurea doses

The RSSDI 2017 diabetes recommendations also note that nausea and vomiting can be limiting adverse effects early in treatment, but the retrieved materials do not provide a current class-wide monitoring or stop-and-continue protocol.

No dedicated ICMR guideline on GLP-1 adverse effects was identified. That gap is worth stating rather than filling with US or European recommendations.

Indian product information fills part of that gap.

CDSCO-approved Indian product information for semaglutide in weight management instructs clinicians to:

• Escalate gradually to reduce gastrointestinal symptoms;
• Delay an increase where significant symptoms persist;
• Prevent dehydration;
• Stop treatment if pancreatitis is suspected and not restart if it is confirmed;
• Adjust insulin or sulfonylurea treatment where needed; and
• Monitor existing diabetic retinopathy closely.

As of September 2026, a CDSCO subject expert committee has recommended safety updates to Indian semaglutide package inserts, including gastroparesis.

Two practical consequences follow.

• First, the package insert supplied with a genuine pack is one of the most India-specific safety documents a patient may receive. That makes the source and authenticity of the pack clinically relevant, not only legally relevant.
• Second, stopping treatment is a monitored decision with its own consequences rather than simply an escape route from a side effect. What happens afterwards is a separate conversation worth having before that decision becomes necessary.

Supervision on this class is not paperwork, and it is not a formality attached to a prescription. A clinician is assessing risk before treatment starts and monitoring how the medicine is tolerated once treatment begins.

Before starting, this includes:

• Previous pancreatitis or gallbladder disease
• A personal or family history of medullary thyroid cancer
• Kidney function
• Eye history in anyone with diabetes
• Other medicines being taken, particularly insulin and sulfonylureas, which can turn a low hypoglycaemia risk into a real one

During treatment, the clinician is watching for:

• Whether the dose should be increased, held or paused
• Hydration and renal function when gastrointestinal losses persist
• Whether an eye assessment is needed where glucose is falling quickly
• Whether a symptom is an expected effect that is improving or something that needs investigating

That judgement is the part no article can supply, and in India it can only come from a registered medical practitioner. If a symptom is persisting, worsening or stopping you from drinking, the useful next step is a consultation with the prescriber who knows the product, your other medicines and your kidney and eye history, rather than a decision made alone. Who is legally permitted to make those calls, and on what basis, is covered in our piece on prescribing GLP-1 medicines in India.

Body composition belongs in that monitoring too. Weight lost on these medicines is not all fat. In the body-composition analysis of SURMOUNT-1, roughly a quarter of the weight lost on tirzepatide over 72 weeks was lean mass.

That loss largely reflects eating less rather than an effect unique to this class, and whether it translates into reduced strength or function over the longer term is not yet settled. Adequate protein and regular resistance exercise are generally advised to limit it, particularly for people already at risk of low muscle or bone mass, including older adults and women after menopause. The pace of weight loss can also affect how much lean mass is lost, which is why protecting muscle during weight loss is part of the wider monitoring conversation.

Not sure whether your symptoms or treatment need closer clinical review? A Voy clinician can look at your medication, symptoms and health history together and advise on the appropriate next step; book a consultation.

This article is for general information and education only and is not medical advice, diagnosis, or treatment. GLP-1 and other medications referenced are prescription-only and are appropriate only for certain people under the supervision of a qualified clinician. Do not start, stop, or change any medication based on this article. Please consult a registered medical practitioner about your individual circumstances. Information reflects what was available at the time of review and may change.